Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.45 |
| ▸ | PPARG | P37231 | 9/20 | 0.42 |
| ▸ | PPARA | Q07869 | 9/20 | 0.42 |
| ▸ | PPARD | Q03181 | 5/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4331394 | 1.00 | MRGPRX4 (0.45) | MRGPRX4PPARGPPARAPPARDPOLB | |
| SCHEMBL4336975 | 0.91 | MRGPRX4 (0.43) | MRGPRX4PPARGPPARAPPARDPOLB | |
| SCHEMBL4327930 | 0.91 | MRGPRX4 (0.43) | MRGPRX4PPARGPPARAPPARDPOLB | |
| SCHEMBL4327927 | 0.91 | MRGPRX4 (0.43) | MRGPRX4PPARGPPARAPPARDPOLB | |
| SCHEMBL4329835 | 0.84 | MRGPRX4 (0.43) | MRGPRX4PPARGPPARAPPARDKMT2A | |
| SCHEMBL4329829 | 0.84 | MRGPRX4 (0.43) | MRGPRX4PPARGPPARAPPARDKMT2A | |
| SCHEMBL4333246 | 0.84 | MRGPRX4 (0.43) | MRGPRX4PPARGPPARAPPARDKMT2A | |
| SCHEMBL4336482 | 0.82 | PPARA (0.53) | MRGPRX4PPARGPPARAPPARDALDH1A1 | |
| SCHEMBL6651371 | 0.82 | PPARA (0.53) | MRGPRX4PPARGPPARAPPARDALDH1A1 | |
| SCHEMBL4336480 | 0.82 | PPARA (0.53) | MRGPRX4PPARGPPARAPPARDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544835-B2 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
| EP-1380562-A1 | CARBOXYLIC ACID DERIVATIVE AND SALT THEREOF | Eisai Co., Ltd. (JP) | 2004-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | GPR119, IRS1, SLC5A1 | MRGPRX4 428/4885PPARG 379/4885PPARA 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.